Regulation of AMPK by the ubiquitin proteasome system

American Journal of Pathology

Volumn 178, Issue 1, 2011, Pages 4-11

  Zungu, Makhosazane ^a   Schisler, Jonathan C ^b   Essop, M Faadiel ^c   McCudden, Chris ^b   Patterson, Cam ^b   Willis, Monte S ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; ATROGIN 1; DEXAMETHASONE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MUSCLE RING FINGER 1 PROTEIN; POLYUBIQUITIN; PROTEASOME; PROTEIN SUBUNIT; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3;

ALPHA CHAIN; BETA CHAIN; CELL ENERGY; ENVIRONMENTAL STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART DISEASE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE HYPERTROPHY; MOLECULAR DYNAMICS; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE; SYNDROME X; UBIQUITINATION; UPREGULATION;

EID: 79251475896     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.11.030     Document Type: Review

References (76)

1. Hardie DG, Hawley SA, Scott JW: AMP-activated protein kinase-development of the energy sensor concept. J Physiol 2006, 574:7-15 (Pubitemid 43905792)
2. Young LH, Li J, Baron SJ, Russell RR: AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc Med 2005, 15:110-118 (Pubitemid 41021735)
3. Hardie DG: Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003, 144: 5179-5183
4. Dyck JR, Lopaschuk GD: AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 2006, 574:95-112
5. Kerscher O, Felberbaum R, Hochstrasser M: Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006, 22:159-180
6. Steinberg GR, Kemp BE: AMPK in Health and Disease. Physiol Rev 2009, 89:1025-1078
7. Woods A, Vertommen D, Neumann D, Turk R, Bayliss J, Schlattner U, Wallimann T, Carling D, Rider MH: Identification of phosphorylation sites in AMP-activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by site-directed mutagenesis. J Biol Chem 2003, 278:28434-28442
8. Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, Jennings IG, Campbell DJ, Witters LA, Parker MW, Kemp BE, Stapleton D: AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol 2003, 13:867-871 (Pubitemid 36573256)
9. Warden SM, Richardson C, O'Donnell J Jr, Stapleton D, Kemp BE, Witters LA: Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization, Biochem J 2001, 354:275-283 (Pubitemid 32209863)
10. Bateman A: The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem Sci 1997, 22:12-13
11. Scott JW, Hawley SA, Green KA, Anis M, Stewart G, Scullion GA, Norman DG, Hardie DG: CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004, 113:274-284
12. Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, House CM, Fernandez CS, Cox T, Witters LA, Kemp BE: Mammalian AMP-activated protein kinase subfamily. J Biol Chem 1996, 271:611-614 (Pubitemid 26034902)
13. Thornton C, Snowden MA, Carling D: Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. J Biol Chem 1998, 273:12443-12450
14. Arad M, Seidman CE, Seidman JG: AMP-activated protein kinase in the heart: role during health and disease. Circ Res 2007, 100:474-488 (Pubitemid 46673257)
15. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D: Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 2000, 346(Pt 3):659-669
16. Hardie DG: Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett 2008, 582:81-89
17. Rosenfeldt F: Heart physiology from cell to circulation. Edited by LH Opie. Philadelphia, Lippincott Williams & Wilkins, 2004, p. 154
18. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D: Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 2006, 281:32207-32216 (Pubitemid 46036775)
19. Nagata D, Hirata Y: The role of AMP-activated protein kinase in the cardiovascular system. Hypertens Res 2010, 33:22-28
20. Davies SP, Helps NR, Cohen PT, Hardie DG: 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett 1995, 377:421-425
21. Anderson KA, Means RL, Huang QH, Kemp BE, Goldstein EG, Selbert MA, Edelman AM, Fremeau RT, Means AR: Components of a calmodulin-dependent protein kinase cascade. Molecular cloning, functional characterization and cellular localization of Ca2+/calmodulin-dependent protein kinase kinase beta. J Biol Chem 1998, 273: 31880-31889
22. Sakamoto K, Zarrinpashneh E, Budas GR, Pouleur AC, Dutta A, Prescott AR, Vanoverschelde JL, Ashworth A, Jovanovic A, Alessi DR, Bertrand L: Deficiency of LKB1 in heart prevents ischemiamediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab 2006, 290:E780-788
23. Gamble J, Lopaschuk GD: Insulin inhibition of 5′ adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation. Metabolism 1997, 46:1270-1274
24. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR: Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 2003, 278:39422-39427
25. Longnus SL, Segalen C, Giudicelli J, Sajan MP, Farese RV, Van Obberghen E: Insulin signalling downstream of protein kinase B is potentiated by 5′AMP-activated protein kinase in rat hearts in vivo. Diabetologia 2005, 48:2591-2601 (Pubitemid 41738227)
26. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K: Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004, 10:1384-1389
27. Shimano M, Ouchi N, Shibata R, Ohashi K, Pimentel DR, Murohara T, Walsh K: Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 2010, 49: 210-220
28. Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini A, Khoury DS, Schneider MD: A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A 2006, 103:17378-17383
29. Wong AK, Howie J, Petrie JR, Lang CC: AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) 2009, 116:607-620
30. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000, 275: 223-228 (Pubitemid 30038975)
31. Owen MR, Doran E, Halestrap AP: Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain, Biochem J 2000, 348(Pt 3):607-614
32. Hawley SA, Gadalla AE, Olsen GS, Hardie DG: The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002, 51: 2420-2425
33. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093-1129 (Pubitemid 40894649)
34. Jorgensen SB, Richter EA, Wojtaszewski JF: Role of AMPK in skeletal muscle metabolic regulation and adaptation in relation to exercise. J Physiol 2006, 574:17-31
35. Dolinsky VW, Dyck JR: Role of AMP-activated protein kinase in healthy and diseased hearts. Am J Physiol Heart Circ Physiol 2006, 291:H2557-2569
36. Lopaschuk GD: AMP-activated protein kinase control of energy metabolism in the ischemic heart. Int J Obes (Lond) 2008, 32(Suppl 4):S29-35
37. Russell RR 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH: AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004, 114:495-503
38. Altarejos JY, Taniguchi M, Clanachan AS, Lopaschuk GD: Myocardial ischemia differentially regulates LKB1 and an alternate 5′-AMP-activated protein kinase. J Biol Chem 2005, 280:183-190
39. Paiva MA, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM: Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther 2010, 24:25-32
40. Nishino Y, Miura T, Miki T, Sakamoto J, Nakamura Y, Ikeda Y, Kobayashi H, Shimamoto K: Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res 2004, 61:610-619 (Pubitemid 38210166)
41. Dyck JR, Kudo N, Barr AJ, Davies SP, Hardie DG, Lopaschuk GD: Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5′-AMP activated protein kinase. Eur J Biochem 1999, 262:184-190 (Pubitemid 29242625)
42. Essop MF, Opie LH: Metabolic therapy for heart failure, Eur Heart J 2004, 25:1765-1768
43. Gollob MH: Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochem Soc Trans 2003, 31:228-231
44. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, Maguire CT, Stapleton D, Schmitt JP, Guo XX, Pizard A, Kupershmidt S, Roden DM, Berul CI, Seidman CE, Seidman JG: Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003, 107:2850-2856
45. Sidhu JS, Rajawat YS, Rami TG, Gollob MH, Wang Z, Yuan R, Marian AJ, DeMayo FJ, Weilbacher D, Taffet GE, Davies JK, Carling D, Khoury DS, Roberts R: Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation 2005, 111:21-29 (Pubitemid 40070839)
46. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, McGarry K, Seidman JG, Seidman CE: Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002, 109:357-362
47. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R: Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001, 104:3030-3033 (Pubitemid 34014052)
48. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ: Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001, 104: 1664-1669
49. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR: Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004, 279: 32771-32779
50. Rodriguez JE, Schisler JC, Patterson C, Willis MS: Seek and destroy: the ubiquitin - proteasome system in cardiac disease. Curr Hypertens Rep 2009, 11:396-405
51. Reyes-Turcu FE, Ventii KH, Wilkinson KD: Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009, 78:363-397
52. Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M, Sano S, Tokunaga F, Tanaka K, Iwai K: A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 2006, 25:4877-4887 (Pubitemid 44607032)
53. Kim HT, Kim KP, Lledias F, Kisselev AF, Scaglione KM, Skowyra D, Gygi SP, Goldberg AL: Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J Biol Chem 2007, 282:17375-17386
54. Ikeda F, Dikic I: Atypical ubiquitin chains: new molecular signals. "Protein modifications: beyond the usual suspects" review series. EMBO Rep 2008, 9:536-542
55. Haglund K, Dikic I: Ubiquitylation and cell signaling. EMBO J 2005, 24:3353-3359
56. Hayden MS, Ghosh S: Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362
57. Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, Alessi DR: Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem J 2008, 411:249-260
58. Witczak CA, Sharoff CG, Goodyear LJ: AMP-activated protein kinase in skeletal muscle: from structure and localization to its role as a master regulator of cellular metabolism. Cell Mol Life Sci 2008, 65: 3737-3755
59. Katz EJ, Isasa M, Crosas B: A new map to understand deubiquitination. Biochem Soc Trans 2010, 38:21-28
60. Shabek N, Ciechanover A: Degradation of ubiquitin: the fate of the cellular reaper. Cell Cycle, 2010, 9:523-530
61. Kimura Y, Tanaka K: Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem 2010, 147:793-798
62. Colland F: The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans, 38:137-143
63. Qi J, Gong J, Zhao T, Zhao J, Lam P, Ye J, Li JZ, Wu J, Zhou HM, Li P: Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue. EMBO J 2008, 27:1537-1548
64. Chastagner P, Israel A, Brou C: Itch/AIP4 mediates Deltex degradation through the formation of K29-linked polyubiquitin chains. EMBO Rep 2006, 7:1147-1153 (Pubitemid 44660572)
65. Moreno D, Viana R, Sanz P: Two-hybrid analysis identifies PSMD11, a non-ATPase subunit of the proteasome, as a novel interaction partner of AMP-activated protein kinase. Int J Biochem Cell Biol 2009, 41:2431-2439
66. Henin N, Vincent MF, Gruber HE, Van den Berghe G: Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 1995, 9:541-546
67. Park H, Kaushik VK, Constant S, Prentki M, Przybytkowski E, Ruderman NB, Saha AK: Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 2002, 277:32571-32577
68. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS: AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002, 277:23977-23980
69. Dubbelhuis PF, Meijer AJ: Hepatic amino acid-dependent signaling is under the control of AMP-dependent protein kinase. FEBS Lett 2002, 521:39-42
70. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoinne A, Hue L, Proud C, Rider M: Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 2002, 12:1419-1423
71. Nakashima K, Yakabe Y: AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription factors in C2C12 myotubes. Biosci Biotechnol Biochem 2007, 71:1650-1656 (Pubitemid 47358716)
72. Krawiec BJ, Nystrom GJ, Frost RA, Jefferson LS, Lang CH: AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. Am J Physiol Endocrinol Metab 2007, 292:E1555-1567
73. Sandri M, Sandri C, Gilbert A, Skurk C, Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412
74. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395-403 (Pubitemid 38591410)
75. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE: Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004, 15:1537-1545 (Pubitemid 38679678)
76. Tong JF, Yan X, Zhu MJ, Du M: AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. J Cell Biochem 2009, 108:458-468